Pruritus – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032
Pruritus, or itching, is a prevalent complaint that dermatologists and primary care physicians frequently encounter. It is one of the most common dermatological issues, and although generally considered harmless, it can negatively impact a patient's well-being and become debilitating when severe. The dermatologic causes of pruritus include conditions such as xerosis (dry skin), atopic dermatitis, scabies, dermatitis herpetiformis, lichen simplex chronicus, psoriasis, lichen planus, contact dermatitis, fungal infections, insect bites, pediculosis (lice infestation), urticaria (hives), sunburn, polymorphous light eruption, pityriasis rosea, as well as triggers like electrostatic charges from nylon and wool friction, plaster of Paris casts, fiberglass, and other irritants. The itch can be classified into four categories: cutaneous itch, neuropathic itch, neurogenic itch, and psychogenic itch. Cutaneous itch, also known as pruritoceptive itch, is caused by skin inflammation. Neuropathic itch occurs due to damage to the nervous system along the afferent nerve pathway and is often observed in conditions like herpetic neuralgia, multiple sclerosis, and brain tumors. Neurogenic itch originates centrally without evidence of neuronal pathology, commonly seen in cholestasis. Lastly, psychogenic itch is associated with delusional states, such as parasitophobia. Histamine is the most prominent substance involved in mediating itch. It is stored in mast cells and keratinocytes. Antihistamines can help treat urticaria and other allergic causes of pruritus. However, apart from providing sedation to aid sleep, antihistamines do not consistently alleviate itch from all causes.
·
In the United States alone, pruritus is a
prevalent symptom leading to over 7 million ambulatory visits yearly.
Thelansis’s “Pruritus Market Outlook,
Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To
2032" covers disease overview, epidemiology, drug utilization,
prescription share analysis, competitive landscape, clinical practice,
regulatory landscape, patient share, market uptake, market forecast, and key
market insights under the potential Pruritus treatment modalities options for
eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).
KOLs insights
of Pruritus across 8 MM market from the centre of Excellence/ Public/ Private
hospitals participated in the study. Insights around current treatment
landscape, epidemiology, clinical characteristics, future treatment paradigm,
and Unmet needs.
Pruritus Market Forecast Patient
Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs
with sourcing, Market Event, and Product Event, Country specific Forecast
Model, Market uptake and patient share uptake, Attribute Analysis, Analog
Analysis, Disease burden, and pricing scenario, Summary, and Insights.
Thelansis Competitive Intelligence (CI) practice
has been established based on a deep understanding of the pharma/biotech
business environment to provide an optimized support system to all levels of
the decision-making process. It enables business leaders in forward-thinking
and proactive decision-making. Thelansis supports scientific and commercial
teams in seamless CI support by creating an AI/ ML-based technology-driven
platform that manages the data flow from primary and secondary sources.
Comments
Post a Comment